Heart Failure Prevention

UCLA Health

K. Watson

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Pharmacologic Options for Managing Obesity in Patients with Heart Fa…

UCLA Health

V. Surampudi

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Acute & Long-Term Cardiac Effects of COVID-19

Stanford Medicine

E. Profita

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Heart Failure Case Presentations

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

B. Greenberg, G. Fonarow, N. Wettersten, M. Rosa Costanzo

Managing Iron Deficiency in Heart Failure: Recognizing the Need for …

Craig Beavers

New Therapeutic Options for the Management of the Hospitalized Patie…

28th Annual Heart Failure 2024: An Update on Therapy

U. Elkayam

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

Challenges and Opportunities with Contemporary GDMT in NYHA Class II…

CVRx | Barostim

W. Abraham

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money